Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.

Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.

Baicalin may effectively treat hair loss by inhibiting 5α-reductase.

Researchers found a specific immune receptor in patients that causes severe skin reactions to a drug.

Leflunomide may lower alopecia areata risk, while other immunomodulators might increase it.

Ezetimibe effectively reduces prostate size in cases of benign prostatic hyperplasia.

Baricitinib slightly increased cholesterol levels in alopecia areata patients, but these changes were manageable.

Activating Tgr5 may help treat hair loss and bone loss.

Dupilumab effectively reduces symptoms of prurigo nodularis and is safe for long-term use.

Tofacitinib was more effective than methotrexate for treating alopecia areata.

Anti-DFS70 antibodies can help identify nonsystemic autoimmune conditions in SLE patients.

Baricitinib at 2mg and 4mg doses improved work productivity and reduced costs for adults with atopic dermatitis.

Berberine may reduce prostate enlargement by blocking inflammation.

RXRα is crucial for proper immune response and links diet to immune function.

Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.

Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.

Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.

Baricitinib might help treat hair loss in lupus patients, but more research is needed.

Blocking IL-8 can reduce skin rashes from cancer treatment.

Apremilast showed mixed results for treating severe alopecia areata.

Ustekinumab significantly improved sexual function and quality of life for people with moderate to severe psoriasis.

Propranolol, flunarizine, and divalproex sodium are equally effective for preventing migraines, but have different side effects.

Alopecia areata patients have fewer protective regulatory B cells, which may contribute to the disease.

Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.

Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.

Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.

Ritlecitinib is an effective new treatment for Alopecia Areata.

The new micelle formulation delivers acne treatment more effectively and safely than current gels.

Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.

Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.